Metabolic consequences of modern immunosuppressive agents in solid organ transplantation
Open accessThe DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Abstract
Among other factors, sophistication of immunosuppressive (IS) regimen accounts for the remarkable success attained in the short- and medium-term solid organ transplant (SOT) survival. The use of steroids, mycophenolate mofetil and calcineurin inhibitors (CNI) have led to annual renal graft survival rates exceeding 90% in the last six decades. On the other hand, attrition rates of the allograft beyond the first year have remained unchanged. In addition, there is a persistent high cardiovascular (CV) mortality rate among transplant recipients with functioning grafts. These shortcomings are in part due to the metabolic effects of steroids, CNI and sirolimus (SRL), all of which are implicated in hypertension, new onset diabetes after transplant (NODAT), and dyslipidemia. In a bid to reduce the required amount of harmful maintenance agents, T-cell-depleting antibodies are increasingly used for induction therapy. The downsides to their use are greater incidence of opportunistic viral infections and malignancy. On the other hand, inadequate immunosuppression causes recurrent rejection episodes and therefore early-onset chronic allograft dysfunction. In addition to the adverse metabolic effects of the steroid rescue needed in these settings, the generated proinflammatory milieu may promote accelerated atherosclerotic disorders, thus setting up a vicious cycle. The recent availability of newer agent, belatacept holds a promise in reducing the incidence of metabolic disorders and hopefully its long-term CV consequences. Although therapeutic drug monitoring as applied to CNI may be helpful, pharmacodynamic tools are needed to promote a customized selection of IS agents that offer the most benefit to an individual without jeopardizing the allograft survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment with n-3 PUFAs 1 g o.d. may confer a small benefit in patients with chronic HF, as shown by a significant 9% relative risk reduction for mortality in the GISSI-HF RCT [475].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [475]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067411 · Cited by 1,810
KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary
Kasiske, B. L., Zeier, M. G., Chapman, J. R., Craig, J. C., Ekberg, H., Garvey, C. A., Green, M. D., Jha, V., Josephson, M. A., Kiberd, B. A., et al. (2010) · Kidney International · doi:10.1038/ki.2009.377 · Cited by 1,735
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Eckardt, K.-U., Kasiske, B. L., & Zeier, M. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02834.x · Cited by 1,499
Adipose tissue dysfunction in obesity, diabetes, and vascular diseases
Hajer, G. R., van Haeften, T. W., & Visseren, F. L. J. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn387 · Cited by 1,410
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
Canalis, E., Mazziotti, G., Giustina, A., & Bilezikian, J. P. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0394-0 · Cited by 1,114
Long-Term Renal Allograft Survival in the United States: A Critical Reappraisal
Lamb, K. E., Lodhi, S., & Meier-Kriesche, H.-U. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03283.x · Cited by 916
Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794
Rapid Loss of Vertebral Mineral Density after Renal Transplantation
Julian, B. A., Laskow, D. A., Dubovsky, J., Dubovsky, E. V., Curtis, J. J., & Quarles, L. D. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108223250804 · Cited by 652 · cited 1×
“Observational study showed there was a positive correlation between cumulative steroid doses, accelerated cancellous bone remodeling, and loss of bone mineral density [Pichett et al. 1996; Julian et al. 1991].”
BackgroundWebster, A. C., Woodroffe, R. C., Taylor, R. S., Chapman, J. R., & Craig, J. C. (2005) · BMJ · doi:10.1136/bmj.38569.471007.ae · Cited by 587
Calcineurin Inhibitor Nephrotoxicity: Longitudinal Assessment by Protocol Histology
Nankivell, B. J., Borrows, R. J., Fung, C. L.-S., O'Connell, P. J., Chapman, J. R., & Allen, R. D. M. (2004) · Transplantation · doi:10.1097/01.tp.0000128636.70499.6e · Cited by 498
Woodle, E. S., First, M. R., Pirsch, J., Shihab, F., Gaber, A. O., & Van Veldhuisen, P. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318187d1da · Cited by 474
Houde, V. P., Brûlé, S., Festuccia, W. T., Blanchard, P.-G., Bellmann, K., Deshaies, Y., & Marette, A. (2010) · Diabetes · doi:10.2337/db09-1324 · Cited by 456 · cited 2×
“Consequently, the reduction in the capacity of adipose tissue clearance of fat results in hyperlipidemia [Houde et al. 2010].”
BackgroundCosio, F. G., Kudva, Y., van der Velde, M., Larson, T. S., Textor, S. C., Griffin, M. D., & Stegall, M. D. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00349.x · Cited by 394
Budde, K., Becker, T., Arns, W., Sommerer, C., Reinke, P., Eisenberger, U., Kramer, S., Fischer, W., Gschaidmeier, H., & Pietruck, F. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62318-5 · Cited by 359
Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients
Johnston, O., Rose, C. L., Webster, A. C., & Gill, J. S. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007111202 · Cited by 359
Lambert, G. W., Straznicky, N. E., Lambert, E. A., Dixon, J. B., & Schlaich, M. P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.002 · Cited by 347 · cited 3×
“Apparently due to its relationship with hepatoportal circulation, truncal adiposity generates proinflammatory milieu by secreting adipokines such as leptin, IL-6 and TNF-a [Hajer et al.”
BackgroundStaatz, C. E., Goodman, L. K., & Tett, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11317550-000000000-00000 · Cited by 343
Staatz, C. E., Goodman, L. K., & Tett, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11317350-000000000-00000 · Cited by 336 · cited 1×
“Furthermore, due to a shared metabolic pathway, there is a pharmacodynamic interaction between steroids, CNI, and SRL, all of which are notable for metabolic side effects [Stratta et al. 2012; Staatz et al. 2010; Ferraris et al. 2011].”
BackgroundVincenti, F., Schena, F. P., Paraskevas, S., Hauser, I. A., Walker, R. G., & Grinyo, J. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.02057.x · Cited by 316 · cited 4×
“Therefore a drug regimen that minimizes the use of these agents is more suitable for those at high risk of allograft rejection but at a lower risk of CV morbidity [Zsom et al. 2015; Vincenti et al. 2008; Krämer et al. 2012].”
BackgroundMethodResultInfluentialGLUCOSE INTOLERANCE AFTER RENAL TRANSPLANTATION DEPENDS UPON PREDNISOLONE DOSE AND RECIPIENT AGE1
Hjelmes??th, J., Hartmann, A., Kofstad, J., Stenstr??m, J., Leivestad, T., Egeland, T., & Fauchald, P. (1997) · Transplantation · doi:10.1097/00007890-199710150-00008 · Cited by 309
Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients
Webster, A. C., Taylor, R. R., Chapman, J. R., & Craig, J. C. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003961.pub2 · Cited by 286
Interleukin 2 receptor antagonists for kidney transplant recipients
Webster, A. C., Ruster, L. P., McGee, R. G., Matheson, S. L., Higgins, G. Y., Willis, N. S., Chapman, J. R., & Craig, J. C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003897.pub3 · Cited by 268
Knight, S. R., & Morris, P. J. (2010) · Transplantation · doi:10.1097/tp.0b013e3181c518cc · Cited by 265 · cited 3×
“Patients placed on such steroid-sparing regimen are characterized by higher rate of acute rejection episodes (AREs) and lower allograft function [Zhang et al. 2013; Knight and Morris, 2010].”
BackgroundInfluentialLebranchu, Y., Thierry, A., Toupance, O., Westeel, P. F., Etienne, I., Thervet, E., Moulin, B., Frouget, T., Le Meur, Y., Glotz, D., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02615.x · Cited by 263 · cited 1×
“The concern that drug-related metabolic (and renal) disorders might shorten allograft survival has led to the use of CNI minimization protocols [Zsom et al. 2015; Gallagher et al. 2004; Lebranchu et al. 2009; Holdaas et al. 2011; Budde et al. 2011].”
BackgroundSteroid avoidance or withdrawal for kidney transplant recipients
Haller, M. C., Royuela, A., Nagler, E. V., Pascual, J., & Webster, A. C. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005632.pub3 · Cited by 258
Teutonico, A., Schena, P. F., & Di Paolo, S. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005050487 · Cited by 239 · cited 1×
“Sirolimus and new onset diabetes after transplant Perhaps due to the variation in study quality, data on the role of SRL in the etiology of NODAT showed inconsistent result [Veroux et al. 2013; Johnston et al. 2008; Gyurus et al. 2011; Teutonico et al. 2005].”
ResultLong-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study
Pichette, V., Bonnardeaux, A., Prudhomme, L., Gagné, M., Cardinal, J., & Ouimet, D. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90138-9 · Cited by 218
Rostaing, L., Vincenti, F., Grinyó, J., Rice, K. M., Bresnahan, B., Steinberg, S., Gang, S., Gaite, L. E., Moal, M.-C., Mondragón-Ramirez, G. A., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12460 · Cited by 197 · cited 1×
“Compared with CsA, it produces a higher rate of early-onset AREs, greater preservation of 12-month allograft function but a similar rate of 5-year graft survival rate [Rostaing et al. 2013].”
BackgroundEffect of obesity on the outcome of kidney transplantation: a 20-year follow-up
Hoogeveen, E. K., Aalten, J., Rothman, K. J., Roodnat, J. I., Mallat, M. J. K., Borm, G., Weimar, W., Hoitsma, A. J., & de Fijter, J. W. (2011) · Transplantation · doi:10.1097/tp.0b013e3182100f3a · Cited by 196 · cited 2×
“Steroids and obesity In children and adults alike, there is an increasing prevalence of exogenous obesity often with an onset in the first year of solid organ transplantation [Denburg et al. 2010; Hoogeveen et al. 2011; Hanevold et al. 2005].”
BackgroundEffects of Obesity on Kidney Transplantation Outcomes: A Systematic Review and Meta-Analysis
Nicoletto, B. B., Fonseca, N. K. O., Manfro, R. C., Gonçalves, L. F. S., Leitão, C. B., & Souza, G. C. (2014) · Transplantation · doi:10.1097/tp.0000000000000028 · Cited by 193 · cited 1×
“However, a recent meta-analysis suggests there may be improving survival of allograft recipients in the modern era compared with those transplanted before the year 2000 [Nicoletto et al. 2014].”
ResultAssessment and Management of Hypertension in Transplant Patients
Weir, M. R., Burgess, E. D., Cooper, J. E., Fenves, A. Z., Goldsmith, D., McKay, D., Mehrotra, A., Mitsnefes, M. M., Sica, D. A., & Taler, S. J. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014080834 · Cited by 190 · cited 1×
“Steroids, calcineurin inhibitors and hypertension The prevalence rate of hypertension in adults with renal transplant ranges from 50–80% while that of pediatric recipients varies from 47–82% [Weir et al. 2015].”
BackgroundRostaing, L., Massari, P., Garcia, V. D., Mancilla-Urrea, E., Nainan, G., Rial, M. D. C., Steinberg, S., Vincenti, F., Shi, R., Di Russo, G., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05840710 · Cited by 188 · cited 1×
“Concern for renal toxicity and metabolic dysregulation has also led to the successful substitution of belatacept for CNI after more than 6 months of treatment [Rostaing et al. 2011; Paz et al. 2014].”
MethodChronic Kidney Disease after Nonrenal Solid-Organ Transplantation
Bloom, R. D., & Reese, P. P. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007040394 · Cited by 183 · cited 3×
“In addition to renal injury from prolonged use, other major adverse effects of CNI are hypertension, NODAT and dyslipidemia [Nankivell et al. 2004; Bloom and Reese, 2007].”
BackgroundInfluentialKnight, S. R., Russell, N. K., Barcena, L., & Morris, P. J. (2009) · Transplantation · doi:10.1097/tp.0b013e3181952623 · Cited by 179
Immunosuppressive drug-induced diabetes
Penfornis, A., & Kury-Paulin, S. (2006) · Diabetes & Metabolism · doi:10.1016/s1262-3636(06)72809-9 · Cited by 173 · cited 1×
“Albeit in high doses, in vitro treatment with CsA has also been shown to produce direct pancreatic toxicity by inducing apoptosis of beta cells [Penfornis and Kury-Paulin, 2006].”
BackgroundKneissel, M., Luong-Nguyen, N.-H., Baptist, M., Cortesi, R., Zumstein-Mecker, S., Kossida, S., O'Reilly, T., Lane, H., & Susa, M. (2004) · Bone · doi:10.1016/j.bone.2004.07.013 · Cited by 159 · cited 1×
“It also decreases the formation of osteocytes with a resultant preservation of cancellous bone mass [Kneissel et al. 2004].”
BackgroundLuan, F. L., Steffick, D., & OJO, A. O. (2011) · Transplantation · doi:10.1097/tp.0b013e318203c25f · Cited by 156 · cited 1×
“Indeed the falling incidence of NODAT in recent times may be related to the lower utilization of steroids in many programs [Cole et al. 2013; Schweer et al. 2014; Hjelmesaeth et al. 1997; Luan et al. 2011].”
BackgroundBone Disease after Renal Transplantation
Weisinger, J. R., Carlini, R. G., Rojas, E., & Bellorín-Font, E. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01510506 · Cited by 146
Holdaas, H., Rostaing, L. P. E., Serón, D., Cole, E., Chapman, J. R., Fellström, B., Strøm, E. H., Jardine, A. G., Midtvedt, K., Machein, U., et al. (2011) · Transplantation · doi:10.1097/tp.0b013e318224c12d · Cited by 141 · cited 1×
“The concern that drug-related metabolic (and renal) disorders might shorten allograft survival has led to the use of CNI minimization protocols [Zsom et al. 2015; Gallagher et al. 2004; Lebranchu et al. 2009; Holdaas et al. 2011; Budde et al. 2011].”
BackgroundHanevold, C. D., Ho, P.-L., Talley, L., & Mitsnefes, M. M. (2005) · Pediatrics · doi:10.1542/peds.2004-0289 · Cited by 136 · cited 1×
“Steroids and obesity In children and adults alike, there is an increasing prevalence of exogenous obesity often with an onset in the first year of solid organ transplantation [Denburg et al. 2010; Hoogeveen et al. 2011; Hanevold et al. 2005].”
BackgroundHirsch, H. H., Yakhontova, K., Lu, M., & Manzetti, J. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13541 · Cited by 135 · cited 1×
“Additional justification for using SRL in place of CNI was rooted in its ability to suppress replication of BK polyomavirus (and therefore prevent BK nephropathy) by interfering with mTOR-S6-Kinase activity [Hirsch et al. 2015].”
BackgroundBelatacept for kidney transplant recipients
Masson, P., Henderson, L., Chapman, J. R., Craig, J. C., & Webster, A. C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010699.pub2 · Cited by 121
Recovery Versus Persistence of Disordered Mineral Metabolism in Kidney Transplant Recipients
Evenepoel, P. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.12.019 · Cited by 118 · cited 3×
“In addition, onset of chronic allograft dysfunction may lead to a persistent metabolic acidosis, 1, 25 vitamin D deficiency, and a more rapid progression of bone disease [Evenepoel, 2013].”
BackgroundInfluentialSympathetic Neural Mechanisms of Cyclosporine-Induced Hypertension*
SANDER, M., LYSON, T., THOMAS, G., & VICTOR, R. (1996) · American Journal of Hypertension · doi:10.1016/0895-7061(96)00288-9 · Cited by 116 · cited 1×
“Aside from steroid contribution and excessive deposition of fat mass, similar to CNI, it causes proangiotensinogen vasoconstrictive endothelial dysfunction [Calò et al. 2002; Rossi and Vella, 2015; Sander et al. 1996; Pourmand et al. 2015; Bailey et al. 2009; Baum and Moe, 2008].”
BackgroundPascual, J., Royuela, A., Galeano, C., Crespo, M., & Zamora, J. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr374 · Cited by 112
Bone disease after renal transplantation
Malluche, H. H., Monier-Faugere, M.-C., & Herberth, J. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.192 · Cited by 110
Tessari, G., & Girolomoni, G. (2012) · Dermatologic Surgery · doi:10.1111/j.1524-4725.2012.02520.x · Cited by 110 · cited 1×
“It is also known for reduction of the more frequent occurrence of nonmelanoma carcinoma in SOT recipients [Tessari and Girolomoni, 2012].”
BackgroundmTORC1 Prevents Preosteoblast Differentiation through the Notch Signaling Pathway
Huang, B., Wang, Y., Wang, W., Chen, J., Lai, P., Liu, Z., Yan, B., Xu, S., Zhang, Z., Zeng, C., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005426 · Cited by 105 · cited 2×
“On the other hand, in vitro studies showed mTOR inhibitor (SRL and EVR) enhances osteoblast differentiation by inactivation of notch pathway and upregulation of Runx2 [Huang et al. 2015].”
BackgroundHöcker, B., Weber, L. T., Feneberg, R., Drube, J., John, U., Fehrenbach, H., Pohl, M., Zimmering, M., Fründ, S., Klaus, G., et al. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp506 · Cited by 103 · cited 1×
“A 2-year RCT of late steroid withdrawal (>3 months) using CsA and MMF as a maintenance therapy showed a positive catch-up growth and a favorable metabolic impact [Höcker et al. 2010].”
BackgroundPrevalence and Causes of Low Bone Density and Fractures in Kidney Transplant Patients
Patel, S., Kwan, J. T. C., McCloskey, E. V., McGee, G., Thomas, G., Johnson, D., Wills, R., Ogunremi, L., & BARRON, J. L. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.10.1863 · Cited by 101 · cited 1×
“Its higher frequency of occurrence also correlates with greater cumulative dose of steroids and a longer pretransplant duration of dialysis [Patel et al. 2001].”
BackgroundMorales, J. M., Marcén, R., del Castillo, D., Andres, A., Gonzalez-Molina, M., Oppenheimer, F., Serón, D., Gil‐Vernet, S., Lampreave, I., Gainza, F. J., et al. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs544 · Cited by 99 · cited 1×
“Steroids and adverse metabolic effects Attempts to eliminate steroids or CNI were motivated by the disproportionate impact of CV disease on the mortality rate among transplant recipients with functioning grafts [Morales et al. 2012].”
BackgroundRisk factors for fractures in kidney transplantation
Shaughnessy, E. A., Dahl, D. C., Smith, C. S., & Kasiske, B. L. (2002) · Transplantation · doi:10.1097/00007890-200208150-00012 · Cited by 98 · cited 1×
“However, there is a failure to confirm the predictive relationship of bone fracture with steroid use in studies with long-term follow up [Malluche et al. 2010; O’Shaughnessy et al. 2002].”
BackgroundSchmidt, S. C., Hamann, S., Langrehr, J. M., Höflich, C., Mittler, J., Jacob, D., & Neuhaus, P. (2007) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s00534-006-1200-7 · Cited by 97
Stratta, P., Quaglia, M., Cena, T., Antoniotti, R., Fenoglio, R., Menegotto, A., Ferrante, D., Genazzani, A. A., Terrazzino, S., & Magnani, C. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1150-0 · Cited by 97
Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients
Morrisett, J. D., Abdel‐Fattah, G., & Kahan, B. D. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00233-1 · Cited by 91 · cited 1×
“Normal lipid levels are restored by about 4 weeks after discontinuation of the drug [Spinelli et al. 2011; Morrisett et al. 2003].”
BackgroundComplications associated with new-onset diabetes after kidney transplantation
Sharif, A., & Baboolal, K. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.174 · Cited by 89 · cited 2×
“Immunosuppressive agents and new onset diabetes after transplant New onset diabetes mellitus is associated with poorer graft survival, higher risk of CV event and greater incidence of patient mortality [Cosio et al. 2005; Israni et al. 2012; Sharif and Baboolai, 2011].”
BackgroundBenfield, M. R., Bartosh, S. M., Iklé, D. N., Warshaw, B. L., Bridges, N. D., Morrison, Y., & Harmon, W. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02767.x · Cited by 83 · cited 2×
“hypertension, NODAT, and dyslipidemia) with the potential for negative impacts on allograft and patient survival [Lloberas et al. 2008; Benfield et al. 2010].”
BackgroundUpala, S., Panichsillapakit, T., Wijarnpreecha, K., Jaruvongvanich, V., & Sanguankeo, A. (2016) · Transplant International · doi:10.1111/tri.12721 · Cited by 81 · cited 1×
“Similarly, there is higher mortality rate in lung transplant recipients with obesity [Upala et al. 2015] and in liver transplant patients with greater amount of abdominal adiposity [Terjimanian et al.”
BackgroundBailey, M. A., Mullins, J. J., & Kenyon, C. J. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.134973 · Cited by 80 · cited 2×
“Indeed there was no evidence for tubular sodium reabsorption, potassium wasting or elevation in plasma renin activity [Bailey et al. 2009].”
BackgroundClaes, K., Meier-Kriesche, H.-U., Schold, J. D., Vanrenterghem, Y., Halloran, P. F., & Ekberg, H. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr238 · Cited by 75 · cited 1×
“The most significant risk factor is the cumulative dose of steroids particularly when used in combination with CsA or SRL [Claes et al. 2012].”
BackgroundCalò, L. A., Davis, P. A., Giacon, B., Pagnin, E., Sartori, M., Riegler, P., Antonello, A., Huber, W., & Semplicini, A. (2002) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200210000-00017 · Cited by 74 · cited 1×
“Finally, the modulatory role of oxidative stress in steroidinduced hypertension was suggested by the concurrent attenuation of both oxygen radicals and hypertension after treatment with ramipril [Calò et al. 2002].”
BackgroundGallagher, M., Hall, B. M., Craig, J. C., Berry, G., TILLER, D. J., & Eris, J. (2004) · Transplantation · doi:10.1097/01.tp.0000144181.47045.fe · Cited by 74
Porrini, E., Delgado, P., Alvarez, A., Cobo, M., Perez, L., Gonzalez-Posada, J. M., Hortal, L., Gallego, R., Garcia, J. J., Checa, M., et al. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm762 · Cited by 74 · cited 1×
“In addition, transplant recipients with prevailing hyperlipidemia, a traditional CV risk factor, are more likely to sustain CNI-induced diabetes mellitus [Porrini et al. 2008].”
BackgroundGyürüs, É., Kaposztas, Z., & Kahan, B. D. (2011) · Transplantation Proceedings · doi:10.1016/j.transproceed.2011.05.001 · Cited by 71 · cited 2×
“Apparently due to its relationship with hepatoportal circulation, truncal adiposity generates proinflammatory milieu by secreting adipokines such as leptin, IL-6 and TNF-a [Hajer et al.”
BackgroundIsrani, A. K., Snyder, J. J., Skeans, M. A., Kasiske, B. L., & for the PORT Investigators (2012) · Transplant International · doi:10.1111/j.1432-2277.2012.01488.x · Cited by 69
Briner, V. A., Thiel, G. T., Monier‐Faugere, M., Bognar, B., Landmann, J., KAMBER, V., & Malluche, H. H. (1995) · Transplantation · doi:10.1097/00007890-199505270-00006 · Cited by 69 · cited 1×
“Calcineurin inhibitors, sirolimus and bone metabolism Due to concurrent use of CNI with steroids, studies on their solitary effect on bone metabolism are limited [Malluche et al. 2010; Marcén et al. 2006; Briner et al. 1995].”
BackgroundPereira, M. J., Palming, J., Rizell, M., Aureliano, M., Carvalho, E., Svensson, M. K. E., & Eriksson, J. W. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1266 · Cited by 67
Einollahi, B., Motalebi, M., Salesi, M., Ebrahimi, M., & Taghipour, M. (2014) · PubMed Central · doi:10.12860/jnp.2014.27 · Cited by 63
Abdominal adiposity, body composition and survival after liver transplantation
Terjimanian, M. N., Harbaugh, C. M., Hussain, A., Olugbade, K. O., Waits, S. A., Wang, S. C., Sonnenday, C. J., & Englesbe, M. J. (2016) · Clinical Transplantation · doi:10.1111/ctr.12688 · Cited by 62
Calcineurin inhibitors in kidney transplantation
Casey, M. J., & Meier‐Kriesche, H. (2011) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32834b4343 · Cited by 61
Corticosteroid-free Kidney Transplantation Improves Growth
Webb, N. J. A., Douglas, S. E., Rajai, A., Roberts, S. A., Grenda, R., Marks, S. D., Watson, A. R., Fitzpatrick, M. M., Vondrák, K., Maxwell, H., et al. (2015) · Transplantation · doi:10.1097/tp.0000000000000498 · Cited by 61
Krämer, B. K., Klinger, M., Vitko, S., Głyda, M., Midtvedt, K., Stefoni, S., Citterio, F., Pietruck, F., Squifflet, J., Segoloni, G., et al. (2012) · Transplantation · doi:10.1097/tp.0b013e31825c1d6c · Cited by 61 · cited 2×
“Therefore a drug regimen that minimizes the use of these agents is more suitable for those at high risk of allograft rejection but at a lower risk of CV morbidity [Zsom et al. 2015; Vincenti et al. 2008; Krämer et al. 2012].”
BackgroundMethodMarcén, R., Caballero, C., Pascual, J., Teruel, J. L., Tenorio, M., Ocaña, J., Villafruela, J. J., Burgos, F., Fernández, A. M., Muriel, A., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000203557.36884.e3 · Cited by 60 · cited 1×
“Calcineurin inhibitors, sirolimus and bone metabolism Due to concurrent use of CNI with steroids, studies on their solitary effect on bone metabolism are limited [Malluche et al. 2010; Marcén et al. 2006; Briner et al. 1995].”
BackgroundSpinelli, G. A., Felipe, C. R., Park, S. I., Sampaio, E. L. M., Junior, H. T. S., & Pestana, J. O. M. (2011) · Transplantation Proceedings · doi:10.1016/j.transproceed.2011.08.074 · Cited by 59
Tornatore, K. M., Biocevich, D. M., Reed, K. A., Tousley, K., Singh, J. P., & Venuto, R. C. (1995) · Transplantation · doi:10.1097/00007890-199503150-00016 · Cited by 58
Unique Cellular and Mitochondrial Defects Mediate FK506-Induced Islet β-Cell Dysfunction
Rostambeigi, N., Lanza, I. R., Dzeja, P. P., Deeds, M. C., Irving, B. A., Reddi, H. V., Madde, P., Zhang, S., Asmann, Y. W., Anderson, J. M., et al. (2011) · Transplantation · doi:10.1097/tp.0b013e3182094a33 · Cited by 55 · cited 1×
“Furthermore, CNI prevents dephosphorylation of cytoplasmic nuclear factor of activated T cells (NFATc), a transcription factor for genes that promotes islet cell proliferation [Rostambeigi et al. 2011].”
BackgroundFerraris, J. R., Argibay, P. F., Costa, L. D., Jiménez, G., Coccia, P. A., Ghezzi, L., Ferraris, V., Belloso, W. H., Redal, M. A., & Larriba, J. (2011) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2011.01513.x · Cited by 55
The effect of methylprednisolone on warm ischemia-reperfusion injury in the liver
Saidi, R. F., Chang, J. C., Verb, S., Brooks, S. E., Nalbantoglu, I., Adsay, V. N., & Jacobs, M. J. (2007) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2006.09.017 · Cited by 53 · cited 1×
“Paradoxically, treatment with low steroid doses on a chronic basis, as currently used in many transplant programs, may downgrade such pro-oxidative tissue inflammation [Saidi et al. 2007].”
BackgroundChoi, S. B., Jang, J. S., Hong, S. M., Jun, D. W., & Park, S. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06400 · Cited by 52
Renal Homotransplantation in 24 Patients
Dunea, G., Nakamoto, S., Straffon, R. A., Figueroa, J. E., Versaci, A. A., Shibagaki, M., & Kolfe, W. J. (1965) · BMJ · doi:10.1136/bmj.1.5426.7 · Cited by 49
Chhabra, D., Skaro, A. I., Leventhal, J. R., Dalal, P., Shah, G., Wang, E., & Gallon, L. G. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06940711 · Cited by 49
mTOR inhibitors in pediatric kidney transplantation
Pape, L., & Ahlenstiel, T. (2013) · Pediatric Nephrology · doi:10.1007/s00467-013-2505-9 · Cited by 47 · cited 2×
“Due to the failure of SRL to meet the high expectations of the transplant community and the unexpected high rate of side effects, there has been a downward trend with its use in the last two decades [Lyster et al. 2004; Pape and Ahlenstiel, 2014].”
BackgroundThe impact of calcineurin inhibitors on graft survival
Rush, D. N. (2013) · Transplantation Reviews · doi:10.1016/j.trre.2013.04.003 · Cited by 47 · cited 1×
“TAC is prescribed to over 96% of patients at the time of hospital discharge for transplant surgery [Rush, 2013].”
BackgroundPamidronate and osteoporosis prevention in liver transplant recipients
Pennisi, P., Trombetti, A., Giostra, E., Mentha, G., Rizzoli, R., & Fiore, C. E. (2006) · Rheumatology International · doi:10.1007/s00296-006-0196-2 · Cited by 45 · cited 1×
“In a prospective study of liver transplant recipients, trabecular bone mineralization was preserved while there was no beneficial effect on the cortical bone mass [Pennisi et al. 2007].”
BackgroundRegulation of bone metabolism in immunosuppressant (FK506)-treated rats
Kirino, S., Fukunaga, J., Ikegami, S., Tsuboi, H., Kimata, M., Nakata, N., Nakano, M., Ueno, T., Mizukawa, N., & Sugahara, T. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-004-0523-1 · Cited by 45 · cited 1×
“Both TAC and CsA stimulate osteoclastic activity in excess of deficit in osteoblastogenesis, and therefore enhance cancellous bone loss [Kirino et al. 2004].”
BackgroundLloberas, N., Torras, J., Alperovich, G., Cruzado, J. M., Gimenez‐Bonafé, P., Herrero, I., Franquesa, M., Rama, I., & Grinyo, J. M. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn223 · Cited by 45 · cited 2×
“hypertension, NODAT, and dyslipidemia) with the potential for negative impacts on allograft and patient survival [Lloberas et al. 2008; Benfield et al. 2010].”
BackgroundVeroux, M., Tallarita, T., Corona, D., Sinagra, N., Giaquinta, A., Zerbo, D., Guerrieri, C., D'Assoro, A., Cimino, S., & Veroux, P. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/496974 · Cited by 44 · cited 1×
“Hence its substitution for CNI has led to the resolution of NODAT in some instances [Veroux et al. 2013].”
BackgroundLangsford, D., & Dwyer, K. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i10.1132 · Cited by 44 · cited 2×
“Hence pretransplant screening for detection of modifiable metabolic events is an appropriate preventive strategy [Juan Khong and Ping Chong, 2014; Langsford and Dwyer, 2015].”
BackgroundFoster, B. J., Martz, K. L., Gowrishankar, M., Stablein, D. M., & Al-Uzri, A. Y. (2010) · Transplantation · doi:10.1097/tp.0b013e3181d3c9be · Cited by 43 · cited 1×
“In addition to steroid use, other risk factors for persistent obesity after transplant are younger age group, remote transplant year, maternal obesity, female gender, lower baseline BMI, and ethnic minority [Boschetti et al. 2013; Denburg et al. 2010; Foster et al. 2010; Vester et al. 2005].”
BackgroundDevelopment of growth and body mass index after pediatric renal transplantation
Vester, U., Schaefer, A., Kranz, B., Wingen, A., Nadalin, S., Paul, A., Malagó, M., Broelsch, C. E., & Hoyer, P. F. (2005) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2005.00304.x · Cited by 42 · cited 2×
“Numerous studies support the etiological role of the cumulative dose of steroids in post-transplant obesity [Denburg et al. 2010; Hoogeveen et al. 2011; Hanevold et al. 2005; Foster et al. 2010; Vester et al. 2005].”
BackgroundResultLyster, H. S., Panicker, G., Leaver, N., & Banner, N. R. (2004) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.10.062 · Cited by 42 · cited 1×
“Due to the failure of SRL to meet the high expectations of the transplant community and the unexpected high rate of side effects, there has been a downward trend with its use in the last two decades [Lyster et al. 2004; Pape and Ahlenstiel, 2014].”
BackgroundGueguen, Y., Ferrari, L., Souidi, M., Batt, A., Lutton, C., Siest, G., & Visvikis, S. (2007) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2007.00066.x · Cited by 41 · cited 2×
“com 119 LDL cholesterol to oxidative milieu [Gueguen et al. 2007].”
BackgroundHumar, A., Gillingham, K., Kandaswamy, R., Payne, W., & Matas, A. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01883.x · Cited by 41
Vadlamudi, S., Hiremagalur, B., Tao, L., Kalhan, S. C., Kalaria, R. N., Kaung, H. C., & Patel, M. S. (1993) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1993.265.4.e565 · Cited by 41
Insulin secretion is decreased in non‐diabetic individuals with hypomagnesaemia
Rodríguez‐Morán, M., & Guerrero‐Romero, F. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1206 · Cited by 40 · cited 3×
“Similarly, free cytosolic calcium ions in other cells may promote insulin resistance by the activation of protein kinase C, a constitutive regulator of insulin receptor substrate [Rodríguez-Morán and Guerrero-Romero, 2011].”
BackgroundInfluentialSoveri, I., Snyder, J. J., Holdaas, H., Holme, I., Jardine, A. G., L'Italien, G. J., & Fellström, B. (2012) · Transplantation · doi:10.1097/tp.0b013e31827722c9 · Cited by 40
Decreased postheparin lipolytic activity in renal transplant recipients with cyclosporin A
Derfler, K., Hayde, M., Heinz, G., Hirschl, M. M., Steger, G., Hauser, A.-C., Balcke, P., & Widhalm, K. (1991) · Kidney International · doi:10.1038/ki.1991.266 · Cited by 39
Guethoff, S., Ströh, K., Grinninger, C., Koenig, M. A., Kleinert, E. C., Rieger, A., Mayr, T., von Ziegler, F., Reichart, B., Hagl, C. M., et al. (2014) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.11.025 · Cited by 35 · cited 1×
“Older recipients of renal transplants are more susceptible to SRL-induced diabetes mellitus [Gyurus et al. 2011].”
BackgroundPrediction of kidney graft failure using clinical scoring tools
Gourishankar, S., Grebe, S. O., & Mueller, T. (2013) · Clinical Transplantation · doi:10.1111/ctr.12135 · Cited by 35
Glucose tolerance before and after renal transplantation
Bergrem, H. A., Valderhaug, T. G., Hartmann, A., Bergrem, H., Hjelmesaeth, J. S., & Jenssen, T. G. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp566 · Cited by 35
Perito, E. R., Lustig, R. H., & Rosenthal, P. J. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13714 · Cited by 34 · cited 1×
“In addition, a greater number of metabolic syndrome components increases the likelihood of developing NODAT [Perito et al. 2016].”
BackgroundOrdonez, L., Bernard, I., Chabod, M., Augusto, J., Lauwers‐Cancès, V., Cristini, C., Cuturi, M. C., Subra, J., & Saoudi, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069791 · Cited by 33 · cited 1×
“In this regard, higher expression of RC isoform of CD45 molecule (CD45RC) on the surfaces of CD8 T cells in pretransplant patients was predictive of rejection events [Ordonez et al. 2013].”
BackgroundPrevention and management of new-onset diabetes mellitus in kidney transplantation.
Khong, M. J., & Chong, C. P. (2014) · PubMed · Cited by 32
Ghanta, M., Kozicky, M., & Jim, B. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000044 · Cited by 32
Meur, Y. L., Thierry, A., Glowacki, F., Rérolle, J.-P., Garrigue, V., Ouali, N., Heng, A.-É., Delahousse, M., Albano, L., Lang, P., et al. (2011) · Transplantation · doi:10.1097/tp.0b013e318234e134 · Cited by 31
Chen, G., Gu, J., Qiu, J., Wang, C., Fei, J.-G., Deng, S., Li, J., Huang, G., Fu, Q., & Chen, L. (2012) · Experimental and Clinical Transplantation · doi:10.6002/ect.2012.0103 · Cited by 31 · cited 3×
“However, the long-lasting immune-suppressive effect of the latter permits the use of lower maintenance doses of steroids or calcineurin inhibitor (CNI) [Chen et al. 2013; Webster et al. 2010].”
BackgroundAblation of Calcineurin Aβ Reveals Hyperlipidemia and Signaling Cross-talks with Phosphodiesterases
Suk, H. Y., Zhou, C., Yang, T. T. C., Zhu, H., Yu, R. Y.-L., Olabisi, O. A., Yang, X., Brancho, D., Kim, J., Scherer, P. E., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.419150 · Cited by 30
Schold, J. D., Poggio, E. D., Goldfarb, D. A., Kayler, L. K., & Flechner, S. M. (2015) · Transplantation · doi:10.1097/tp.0000000000000507 · Cited by 30 · cited 2×
“The depletional agents are superior to interleukin (IL)-2 receptor agonists in efficacy but are associated with higher rates of opportunistic viral infection and malignancy [Chen et al. 2013; Pascual et al. 2009; Schold et al. 2015].”
BackgroundIng, S. W., Sinnott, L. T., Donepudi, S., Davies, E. A., Pelletier, R. P., & Lane, N. E. (2010) · Clinical Transplantation · doi:10.1111/j.1399-0012.2010.01344.x · Cited by 29 · cited 1×
“In addition, patients on a GC-withdrawal protocol had a net gain in bone mineral density; a benefit that was more pronounced in patients with severe kidney disease [Ing et al. 2011].”
BackgroundEffects of deflazacort vs. methylprednisone: a randomized study in kidney transplant patients
The Deflazacort Study Group, Ferraris, J. R., Pasqualini, T., Alonso, G., Legal, S., Sorroche, P. B., Galich, A. M., & Jasper, H. (2007) · Pediatric Nephrology · doi:10.1007/s00467-006-0403-0 · Cited by 28
Zsom, L., Wagner, L., & Fülöp, T. (2015) · World Journal of Transplantation · doi:10.5500/wjt.v5.i3.73 · Cited by 27 · cited 8×
“Adverse effects of prolonged steroid use include hyperlipidemia, growth retardation, obesity, insulin resistance, hypertension, and metabolic bone diseases [Zsom et al. 2015].”
BackgroundMethodInfluentialGlucocorticoid-Mediated Hypertension
Baum, M. G., & Moe, O. W. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008040410 · Cited by 25 · cited 6×
“This was experimentally demonstrated by the blockade of steroid-promoted hypertension after an infusion of L-arginine [Baum and Moe, 2008].”
BackgroundInfluentialPadiyar, A., Augustine, J. J., Bodziak, K. A., Aeder, M. I., Schulak, J. A., & Hricik, D. E. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.02.081 · Cited by 24
Hypertension, Living Kidney Donors, and Transplantation: Where Are We Today?
Rossi, A., & Vella, J. P. (2015) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2015.01.002 · Cited by 23 · cited 18×
“Patients placed on such steroid-sparing regimen are characterized by higher rate of acute rejection episodes (AREs) and lower allograft function [Zhang et al.”
BackgroundInfluentialSchweer, T., Gwinner, W., Scheffner, I., Schwarz, A., Haller, H. G., & Blume, C. A. (2014) · Clinical Transplantation · doi:10.1111/ctr.12329 · Cited by 23
Gnatta, D., Keitel, E. E., Heineck, I., Cardoso, B. D., Rodrigues, A. P. O., Michel, K., & Garcı́a, V. D. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.02.021 · Cited by 22
Yao, B., Chen, X., Shen, F., Xu, W., Dong, T., Chen, L.-Z., & Weng, J. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2012.08.019 · Cited by 21
Cole, E., Prasad, G. V. R., Cardella, C. J., Kim, J. S., Tinckam, K. J., Cattran, D., Schiff, J. R., Landsberg, D. N., Zaltzman, J. S., & Gill, J. S. (2013) · Transplantation Research · doi:10.1186/2047-1440-2-1 · Cited by 21
Barbosa, S. B. B., Nogueira, P. C. K., Pereira, A. M. L., Fisberg, M., & Pestana, J. O. M. (2012) · Pediatric Transplantation · doi:10.1111/petr.12020 · Cited by 19
Longitudinal relations between obesity and hypertension following pediatric renal transplantation
Denburg, M., Pradhan, M., Justine Shults, A., Jones, A., Palmer, J. A., Baluarte, H. J., & Leonard, M. B. (2010) · Pediatric Nephrology · doi:10.1007/s00467-010-1572-4 · Cited by 18
Cyclosporine A and palmitic acid treatment synergistically induce cytotoxicity in HepG2 cells
Luo, Y., Rana, P., & Will, Y. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.03.022 · Cited by 17 · cited 1×
“CsA toxicity may be aggravated by a higher serum level of saturated fatty acid, which may be seen in patients with steroid-induced obesity and druginduced hyperlipidemia [Luo et al. 2012].”
BackgroundChan, L. K., Andrés, A., Bunnapradist, S., Gugliuzza, K., Parasuraman, R., Peddi, V. R., Cassuto, É., & Hart, M. E. (2012) · Journal of Transplantation · doi:10.1155/2012/941640 · Cited by 15
Turgay, M., Turgay, F., Devrím, E., Küçükşahin, O., Çaydere, M., & Durak, İ. (2012) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2012_002 · Cited by 14
Is it safe to withdraw steroids within seven days of renal transplantation?
Zhang, X., Huang, H., Han, S., Fu, S., & Wang, L. (2012) · Clinical Transplantation · doi:10.1111/ctr.12015 · Cited by 13
Burkhalter, F., Oettl, T., Descoeudres, B., Bachmann, A., Guerke, L., Mihatsch, M. J., Dickenmann, M., & Steiger, J. U. (2012) · Transplantation Proceedings · doi:10.1016/j.transproceed.2012.07.142 · Cited by 12
Sugioka, N., Kokuhu, T., Okamoto, M., Yoshimura, N., Ιtο, Y., Shibata, N., & Takada, K. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.9.0005 · Cited by 12
Pazik, J., Ołdak, M., Lewandowski, Z., Podgórska, M., Sitarek, E., Płoski, R., Gałązka, Z., Kwiatkowski, A., Malejczyk, J., & Durlik, M. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2013.01.010 · Cited by 11
Conversion to Belatacept-Based Immunosuppression Therapy in Renal Transplant Patients
Paz, M., Roberti, J. E., Mos, F., & Cicora, F. (2014) · Transplantation Proceedings · doi:10.1016/j.transproceed.2014.07.003 · Cited by 11
The impact of diabetes on ethnic disparities seen in kidney transplantation.
Taber, D. J., Meadows, H. B., Pilch, N. A., Chavin, K. D., Baliga, P. K., & Egede, L. E. (2013) · PubMed · Cited by 11
Lipid disturbances before and after renal transplant.
Razeghi, E., Shafipour, M., Ashraf, H., & Pourmand, G. (2011) · PubMed · Cited by 11
Steroid Elimination—Who, When, How?
Matas, A. J. (2008) · Transplantation Proceedings · doi:10.1016/j.transproceed.2008.10.007 · Cited by 10 · cited 15×
“Patients placed on such steroid-sparing regimen are characterized by higher rate of acute rejection episodes (AREs) and lower allograft function [Zhang et al.”
BackgroundInfluentialJiménez, S., Marcén, R., Vaamonde, C., Caballero, C., Fernández‐Rodríguez, A., Villafruela, J. J., Galeano, C., Teruel, J. L., & Quereda, C. (2015) · Clinical Transplantation · doi:10.1111/ctr.12666 · Cited by 10 · cited 1×
“Perhaps for these reasons, vertebral fracture occurs at a higher rate than in the general population as observed in a cross sectional study [Jiménez et al. 2015].”
Tacrolimus versus cyclosporine for early steroid withdrawal after renal transplantation
Sandrini, S., Aslam, N., Tardanico, R., Setti, G., Bossini, N., Valerio, F., Insalaco, M., Maffeis, R., Nodari, F., & Cancarini, G. C. (2011) · Journal of Nephrology · doi:10.5301/jn.5000070 · Cited by 10 · cited 1×
“Although TAC shared a similar mechanism of action with CsA, it has a lower acute rejection (AR) rate and produces a more favorable CV profile [Sandrini et al. 2012; Bakar et al. 2009; Webster et al. 2005a].”
BackgroundBakar‐Ates, F., Keven, K., Doğru, B., Aktan, F., Ertürk, Ş., Tüzüner, A., Erbay, B., & Nebioğlu, S. (2009) · Transplantation Proceedings · doi:10.1016/j.transproceed.2009.01.091 · Cited by 9 · cited 2×
“Indeed a switch to TAC from a CsA-based regimen is associated with resolution of hyperlipidemia [Bakar et al. 2009].”
BackgroundYong, K., Nguyen, H. D., Hii, L., Chan, D. T., Boudville, N. C., Messineo, A., Lim, E. M., Dogra, G. K., & Lim, W. H. (2013) · American Journal of Hypertension · doi:10.1093/ajh/hpt017 · Cited by 9
Does hypertension remain after kidney transplantation?
Pourmand, G., Dehghani, S., Rahmati, M. R., Mehrsai, A., Gooran, S., Alizadeh, F., Khaki, S., Mortazavi, S. H., & Pourmand, N. (2015) · PubMed · Cited by 8
Takeuchi, H., Matsuno, N., Hirano, T., Gulimire, M., Hama, K., Nakamura, Y., Iwamoto, H., Toraishi, T., Kawaguchi, T., Okuyama, K., et al. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1578 · Cited by 8 · cited 1×
“For instance, measurement of lymphocyte proliferation in response to a given amount of endogenous cortisol identified those who are likely to fail steroid withdrawal [Takeuchi et al. 2011].”
BackgroundI.Khalil, W. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/15594.7003 · Cited by 7 · cited 1×
“On the other hand, hyperleptinemia promotes insulin resistance; it causes an increase in fasting plasma insulin, post-prandial hyperglycemia and decreased mRNA expression of insulin receptors in skeletal muscle [Wjidan et al. 2015].”
BackgroundNumber of Antihypertensive Drugs at 1 Year After Kidney Transplantation
Kislikova, M., Seras, M., Monfá, E., Rodrigo, E., Fernández‐Fresnedo, G., Ruiz, J. C., & Arias, M. (2015) · Transplantation Proceedings · doi:10.1016/j.transproceed.2014.12.009 · Cited by 6 · cited 1×
“Poor blood pressure control is not uncommon thereby justifying the need for multiple antihypertensive agents [Kislikova et al. 2015].”
BackgroundWang, R., Xü, Y., Wu, J., Wang, Y., He, Q., & Chen, J. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8457 · Cited by 2 · cited 1×
“However, such an approach may result in a greater frequency of late-onset AR events [Wang et al. 2013; Burkhalter et al. 2012].”
Background
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“These effects vary with different immunosuppressive drugs.(497,498,502) 506 The management of dyslipidaemias in transplant recipients is comparable to what is recommended for patients at high or very high ASCVD risk, although more attention is needed regarding the causes of the lipid disturbances and possible side eff…”
Esterline, R. L., Vaag, A., Oscarsson, J., & Vora, J. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0832 · Cited by 98
Metz, D., Holford, N. H. G., Kausman, J., Walker, A., Cranswick, N., Staatz, C. E., Barraclough, K. A., & Ierino, F. L. (2019) · Transplantation · doi:10.1097/tp.0000000000002762 · Cited by 80
Metabolic Consequences of Solid Organ Transplantation
Bhat, M., Usmani, S. E., Azhie, A., & Woo, M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa030 · Cited by 80
Metadata
- Authors
- Bamgbola, O.
- Affiliations
- SUNY Downstate Health Sciences University (US)
- Corresponding author
- Bamgbola, Oluwatoyin
- ORCID
- Bamgbola, Oluwatoyin
- Venue
- Therapeutic Advances in Endocrinology and Metabolism
- Publisher
- SAGE Publications
- Published
- 2016-03-30
- Volume
- 7
- Issue
- 3
- Pages
- 110-127
- ISSN
- 2042-0188 (ISSN-L)
- 2042-0196
- PMC
- PMC4892400
- OpenAlex
- W2320017047
- Cited by
- 85
- References
- 141
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 7 · 2023: 2 · 2022: 12 · 2021: 12 · 2020: 6 · 2019: 9 · 2018: 8 · 2017: 11 · 2016: 3
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Endocrinology and Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Transplantation › Organ and Tissue Transplantation Research
- Keywords
- immunosuppressants, solid organ transplantation, metabolic complications, calcineurin inhibitors, rapamycin, corticosteroids, mycophenolate mofetil, post-transplant diabetes mellitus, hypertension, dyslipidemia, cardiovascular mortality, belatacept, chronic allograft dysfunction, atherosclerosis, therapeutic drug monitoring, personalized immunosuppression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.